Arthritis & Rheumatism, Volume 63,
November 2011 Abstract Supplement
Abstracts of the American College of
Rheumatology/Association of Rheumatology Health Professionals
Annual Scientific Meeting
Chicago, Illinois November 4-9, 2011.
The Presence of HLA-B15 Determines the Clinical Presentation and Outcome in Colombian's Patients with Spondyloarthropathies.
Londono1, John, Pena2, Paola, Santos3, Ana, Bautista-Molano2, Wilson, Sanchez2, Consuelo Romero, Avila4, Mabel, Porras4, Marlon
Universidad de La Sabana, Chía, Colombia
Spondyloarthritis Group. Rheumatology Division. Hospital Militar Central/Universidad de La Sabana. Bogotá. Colombia, Bogotá, Colombia
Universidad de Los Andes, Bogota, Colombia
Spondyloarthritis Group. Rheumatology Division. Hospital Militar Central/Universidad de La Sabana. Bogotá. Colombia, Bogota, Colombia
Instituto Nacional de Cardiologia Ignacio Chavez, Ciudad de Mexico DF, Mexico
Spondyloarthritis Group. Rheumatology Division. Hospital Militar Central/Universidad de La Sabana, Bogotá, Colombia
Background/Purpose:
In patients with Spondyloarthropathies (SpA) the association with the HLA-B15 has been previously established: 35/228 patients were positive for this allele, while only was present in 2/100 controls: OR 5.3CI95%: 1.8–17.6. (EULAR2011–4847).To determine differences in clinical presentation and outcomes of the disease among HLA-B15+, HLA-B27+ and non B27-B15 patients.
Methods:
435 of a total of 574 patients with SpA according to ESSG classification criteria and had completed HLA typing were selected. Comparisons with HLA-B27+, B15 and non B27-B15 were made to the main clinical features; disease-related background and the commitment level of the sacroiliac joints.
Results:
The main findings are presented in the table:
| VARIABLE | HLA-B15(+) n=52 | HLA-B27(+) n=179 | OTHER HLA-B n=203 |
|---|---|---|---|
| Age (y) | 31.8 ± 10.6 | 34.9 ± 10.1 | 35.5 ± 13.03 |
| Age of onset (y) | 26.9 ± 9.2 | 27.3 ± 10.4 | 29.2 ± 10.6 |
| Evolution (y) | 4.7 ± 5.2* | 7.9 ± 10.3 | 6.4 ± 8.6 |
| Sex(M/F) | 33/19 1.7:1* | 145/34 4.2:1 | 128/76 1.6:1 |
| u-SpA | 25 (48.1%)* | 35 (19.6%) | 102 (50.2%) |
| AS | 10 (19.2%) | 92 (51.4%)* | 43 (21.2%) |
| ReA | 17 (32.7%)* | 51 (28.5%) | 47 (23.2%) |
| PsA | 0 (0%) | 1 (0.1%) | 11 (5.4%) |
| Family history for SpA | 5 (9.6%)* | 10 (5.6%) | 12 (5.9%) |
| Inflammatory back pain | 11 (21.1%) | 50 (27.9%) | 60 (29.5%) |
| SCHOBER | 15.4 ± 3.7 | 14.7 ± 2.9 | 14.7 ± 2.1 |
| X-ray Sacroilitis <II | 26 (50%)* | 51 (28.6%) | 151 (74.4%) |
| X-ray Sacroilitis >=II | 26 (50%) | 128 (71.4%)* | 52 (25.6%) |
| Occiput to wall distance (cm) | 0.2 ± 1.4 | 1.3 ± 3.5 | 0.5 ± 1.7 |
| ASAS Axial criteria | 36 (69.2%) | 178 (99.4%)* | 84 (41.4%) |
| ASAS Peripheral criteria | 41 (78.8%) | 161 (89.9%) | 203 (100%) |
Conclusion:
Patients HLA-B15 positive initiated the disease at an earlier age and had a shorter time of evolution, the predominance of males was lower, with a greater proportion of patients with u-SpA and a lower degree of compromise of sacroiliacs joint. This seems to be a pattern of presentation of the disease.
To cite this abstract, please use the following information:
Londono, John, Pena, Paola, Santos, Ana, Bautista-Molano, Wilson, Sanchez, Consuelo Romero, Avila, Mabel, et al; The Presence of HLA-B15 Determines the Clinical Presentation and Outcome in Colombian's Patients with Spondyloarthropathies. [abstract]. Arthritis Rheum 2011;63 Suppl 10 :542
DOI:
